CClinicalTrials.gg
CompletedNCT03626168MOXIEUpdated May 17, 2022Results posted

Bioactive Compounds in Watermelon Modulating Oxidative Stress and Inflammation in Elders

An interventional study of 100% watermelon juice and Placebo beverage in Arterial Stiffness and Inflammation, sponsored by University of Alabama, Tuscaloosa. Completed. Open to female participants aged 55 Years to 69 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-05-17.

Sponsored by University of Alabama, Tuscaloosa · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Registered 2 years 5 months after the study started (first participant enrolled Feb 2016, registered Jul 2018).
Phase
Not applicable
Study type
Interventional
Enrollment
21
Allocation
Non-randomized
Ages
55 Years to 69 Years
Sex
Female
01

Study summary

Watermelon is the only food with a unique combination of amino acids and antioxidants that may reduce artery stiffness. However, only 27% of older adults meet the daily recommendation for fruit intake. Because it tastes good and is convenient and easy to consume, watermelon juice is an innovative and impactful intervention to help elders easily meet recommendations for fruit servings. If effective, this intervention would be a simple, inexpensive way to combat cardiovascular diseases (CVD). Results will advance science by providing a better understanding whether four-week consumption of 100% watermelon juice may impact measures of vascular health and inflammation in postmenopausal women.

Read the detailed description

Purpose and Objectives:

Vascular endothelial dysfunction is an early independent predictor of cardiovascular diseases (CVD), the leading cause of death for women ages 60 and older in the United States1. It is well-known that age-related decreases in vascular endothelial function are partially due to increases in oxidative stress and inflammation.In attempts to combat CVD, previous intervention studies have investigated provision of isolated bioactive food compounds (BFC) in supplemental form. For example, purified lycopene has been shown to decrease oxidative stress, and our previous work supports the supplemental use of glutamine and arginine in improving vascular endothelial function of older adults. Arginine is a precursor for the vasodilatory molecule nitric oxide (NO), and both glutamine and arginine have been shown to attenuate inflammation. Thus, if supplemented together, these compounds would be expected to exert synergist mechanistic effects that improve vascular function.

Watermelon is one of the richest sources of lycopene, and it is among the greatest plant sources of arginine and glutamine. Watermelon also provides high amounts of citrulline (a precursor of arginine) along with the antioxidant ascorbic acid, which enhances the antioxidant and anti-inflammatory effects of carotenoids such as lycopene in biological samples. To date, clinical studies evaluating the potential synergy of these compounds provided by the whole food are lacking on mechanistic and clinical outcomes of CVD. The effects of watermelon supplementation on robust measures of vascular function, inflammation, and oxidative stress in women ages 60 and older are unknown. This study will evaluate the possible impact of multiple bioactive compounds in the natural food matrix of watermelon in order to fully characterize their potential synergy and their influence on CVD risk. Specifically, our proposed study seeks to evaluate the influence of bioactive compounds in 100% watermelon juice, a convenient serving alternative to fresh fruit, using a randomized, double-blind placebo-controlled trial with a crossover design.

Specific Aims:

  1. Mechanistic: To determine whether community-dwelling, non-obese women ages 55-69 consuming two 12-ounce servings of 100% watermelon juice per day versus placebo for four weeks will demonstrate:

    1. increases in circulating levels of serum lycopene, citrulline, and arginine using ultra high performance liquid chromatography with photodiode array detector (UPLC-PDA).
    2. improvement in antioxidant status as assessed by the oxygen radical absorbance capacity assay (ORAC) of whole and deproteinated serum
    3. decreases in circulating biomarkers of inflammation Hypotheses: Four-week dietary supplementation with 100% watermelon juice will result in increased antioxidant capacity and decreased inflammation, related to increased serum lycopene, citrulline, and arginine
  2. Clinical: To determine whether community-dwelling, women ages 55-69 consuming two 12-ounce servings of 100% watermelon juice per day versus placebo for four weeks will exhibit:

    1. improved vascular endothelial function as assessed by flow-mediated dilation (FMD) and decreased arterial stiffness as assessed by pulse wave analysis (PWA)
    2. decreased low density lipoprotein (LDL) oxidation as assessed by enzyme immunoassay Hypotheses: Four-week dietary supplementation with 100% watermelon juice will result in improved vascular endothelial function, decreased arterial stiffness, and decreased LDL oxidation.
02

Conditions studied

  • Arterial Stiffness
  • Inflammation

Browse trials for

03

In context

Inflammation

3,439 studies on the registry are indexed under Inflammation; 629 are open to participants now.

This study's enrollment of 21 is below the median of 50 across 2,437 interventional studies indexed under Inflammation.

Browse Inflammation studies →

Lead sponsor

University of Alabama, Tuscaloosa is the lead sponsor of 39 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
55 Years to 69 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • Ambulatory
  • Female
  • Age 55-69 years
  • Body mass index 18.5 - 29.9 kg/m2 (non-obese)

Exclusion criteria

Exclusion Criteria:

  • Food allergy to watermelon
  • History of hypotension, chronic hypertension, chronic kidney disease, diabetes, previous cardiac events or procedures, phenylketonuria
  • Smoking or other tobacco use
  • Use of anticoagulant medications, cholesterol-lowering medications, blood-pressure medications, vasodilatory dietary supplements (garlic, fish oil), or dietary supplements containing lycopene, ascorbic acid, L-glutamine, L-arginine, or L-citrulline
  • Weight change > 10% in the previous year
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
21 participants (actual)

Study arms

  • Active comparator
    Consumption of 100% watermelon juice

    Consumption of two 12-ounce doses of pasteurized 100% watermelon juice for a four-week period

    Dietary Supplement: 100% watermelon juice

  • Placebo comparator
    Consumption of a placebo beverage

    Consumption of a placebo beverage with comparable sugar content, pH, taste, texture, and color for a four-week period

    Other: Placebo beverage

Interventions

  • Dietary supplement100% watermelon juice

    Participants drank two 12-ounce servings of 100% watermelon juice per day for a four-week period.

  • OtherPlacebo beverage

    Participants drank two 12-ounce servings of a placebo beverage per day for a four-week period.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Serum Levels of Lycopene at 4 Weeks

    Lycopene determined by ultra high performance liquid chromatography with photodiode array detector (UPLC-PDA).

    Time frame: Baseline and 4 Weeks

  2. Change in Vascular Endothelial Function at 4 Weeks

    Determined by brachial artery flow-mediated dilation (FMD). FMD uses ultrasound technology to quantify changes in brachial artery diameter in response to hyperemia. A blood pressure cuff was placed distal to the brachial artery of the right arm with the participant supine and rested. Pre-inflation diameter was recorded for one minute, and the cuff was inflated to 50 mmHg above resting SBP for five minutes. Then, images were recorded for 120 seconds after cuff deflation. Peak diameter was determined as an average of the five highest measurements over five seconds post-deflation. FMD was expressed as the percentage increase in peak diameter.

    Time frame: Baseline and 4 weeks

  3. Change in Arterial Stiffness at 4 Weeks

    Determined by pulse wave velocity (PWV). A cuff-based system was used to measure brachial oscillometric pressure waveforms and generate central pressure curves by propriety algorithms. PWV was quantified as the rate at which a pulse wave moves down a vessel.

    Time frame: Baseline and 4 weeks

07

Results

Posted May 17, 2022

Participant flow

First Intervention (4 Weeks)
Participant flow — First Intervention (4 Weeks)
Milestone100% Watermelon Juice First, Then Placebo BeveragePlacebo Beverage First, Then 100% Watermelon Juice
Started912
Completed811
Not completed11
Withdrew: Withdrawal by subject10
Withdrew: Began a medication that precluded participation01
Washout (2 Weeks)
Participant flow — Washout (2 Weeks)
Milestone100% Watermelon Juice First, Then Placebo BeveragePlacebo Beverage First, Then 100% Watermelon Juice
Started811
Completed811
Not completed00
Second Intervention (4 Weeks)
Participant flow — Second Intervention (4 Weeks)
Milestone100% Watermelon Juice First, Then Placebo BeveragePlacebo Beverage First, Then 100% Watermelon Juice
Started811
Completed89
Not completed02
Withdrew: Withdrawal by subject02

Outcome measures

PrimaryChange From Baseline in Serum Levels of Lycopene at 4 Weeks

Lycopene determined by ultra high performance liquid chromatography with photodiode array detector (UPLC-PDA).

Time frame:
Baseline and 4 Weeks
Reported as:
Mean · uM
Change From Baseline in Serum Levels of Lycopene at 4 Weeks
uMConsumption of 100% Watermelon JuiceConsumption of a Placebo Beverage
Change From Baseline in Serum Levels of Lycopene at 4 Weeks7.30 ± 7.553.09 ± 4.92
PrimaryChange in Vascular Endothelial Function at 4 Weeks

Determined by brachial artery flow-mediated dilation (FMD). FMD uses ultrasound technology to quantify changes in brachial artery diameter in response to hyperemia. A blood pressure cuff was placed distal to the brachial artery of the right arm with the participant supine and rested. Pre-inflation diameter was recorded for one minute, and the cuff was inflated to 50 mmHg above resting SBP for five minutes. Then, images were recorded for 120 seconds after cuff deflation. Peak diameter was determined as an average of the five highest measurements over five seconds post-deflation. FMD was expressed as the percentage increase in peak diameter.

Time frame:
Baseline and 4 weeks
Reported as:
Mean · percentage of change in diameter
Change in Vascular Endothelial Function at 4 Weeks
percentage of change in diameterConsumption of 100% Watermelon JuiceConsumption of a Placebo Beverage
Change in Vascular Endothelial Function at 4 Weeks2.85 ± 7.812.17 ± 9.25
PrimaryChange in Arterial Stiffness at 4 Weeks

Determined by pulse wave velocity (PWV). A cuff-based system was used to measure brachial oscillometric pressure waveforms and generate central pressure curves by propriety algorithms. PWV was quantified as the rate at which a pulse wave moves down a vessel.

Time frame:
Baseline and 4 weeks
Reported as:
Mean · meters/second
Change in Arterial Stiffness at 4 Weeks
meters/secondConsumption of 100% Watermelon JuiceConsumption of a Placebo Beverage
Change in Arterial Stiffness at 4 Weeks-0.029 ± 0.269-0.188 ± 0.486

Adverse events

Collected over Four weeks for each intervention. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Consumption of 100% Watermelon Juice0/17 (0%)0/17 (0%)0/17 (0%)
Consumption of a Placebo Beverage0/17 (0%)0/17 (0%)0/17 (0%)

Baseline characteristics

One participant was randomized, but she began taking a hypertension medication that precluded her participation prior to baseline testing. Three other participants withdrew from the study before completion, but they completed baseline testing.

Age, Continuous
Age, Continuous(years)100% Watermelon Juice First, Then Placebo BeveragePlacebo Beverage First, Then 100% Watermelon JuiceTotal
Mean61.78 ± 4.9958.91 ± 2.9160.20 ± 4.14
Sex: Female, Male
Sex: Female, Male(Participants)100% Watermelon Juice First, Then Placebo BeveragePlacebo Beverage First, Then 100% Watermelon JuiceTotal
Female91120
Male000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)100% Watermelon Juice First, Then Placebo BeveragePlacebo Beverage First, Then 100% Watermelon JuiceTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White91120
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)100% Watermelon Juice First, Then Placebo BeveragePlacebo Beverage First, Then 100% Watermelon JuiceTotal
United States91120
Weight
Weight(kg)100% Watermelon Juice First, Then Placebo BeveragePlacebo Beverage First, Then 100% Watermelon JuiceTotal
Mean59.69 ± 10.0769.96 ± 5.7565.34 ± 9.36
Body mass index (BMI)
Body mass index (BMI)(kg/m^2)100% Watermelon Juice First, Then Placebo BeveragePlacebo Beverage First, Then 100% Watermelon JuiceTotal
Mean22.61 ± 3.2127.12 ± 2.5125.08 ± 3.60
Serum lycopene
Serum lycopene(uM)100% Watermelon Juice First, Then Placebo BeveragePlacebo Beverage First, Then 100% Watermelon JuiceTotal
Mean1.55 ± 0.701.26 ± 0.871.37 ± 0.80
Serum arginine
Serum arginine(uM)100% Watermelon Juice First, Then Placebo BeveragePlacebo Beverage First, Then 100% Watermelon JuiceTotal
Mean65.51 ± 24.5454.64 ± 16.1058.87 ± 19.87

6 further baseline measures are reported on the registry.

08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Ellis AC, Dudenbostel T, Locher JL, Crowe-White K. Modulating Oxidative Stress and Inflammation in Elders: The MOXIE Study. J Nutr Gerontol Geriatr. 2016 Oct-Dec;35(4):219-242. doi: 10.1080/21551197.2016.1250693. PubMed 27897608 ↗
  • Ellis AC, Mehta T, Nagabooshanam VA, Dudenbostel T, Locher JL, Crowe-White KM. Daily 100% watermelon juice consumption and vascular function among postmenopausal women: A randomized controlled trial. Nutr Metab Cardiovasc Dis. 2021 Sep 22;31(10):2959-2968. doi: 10.1016/j.numecd.2021.06.022. Epub 2021 Jul 7. PubMed 34344546 ↗
  • Crowe-White KM, Voruganti VS, Talevi V, Dudenbostel T, Nagabooshanam VA, Locher JL, Ellis AC. Variation of Serum Lycopene in Response to 100% Watermelon Juice: An Exploratory Analysis of Genetic Variants in a Randomized Controlled Crossover Study. Curr Dev Nutr. 2020 Jun 17;4(7):nzaa102. doi: 10.1093/cdn/nzaa102. eCollection 2020 Jul. PubMed 32695957 ↗

Study documents

  • Protocol and statistical analysis plan · Feb 16, 2016
  • Informed consent form · Oct 12, 2018

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 17, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03626168
Lead sponsor
University of Alabama, Tuscaloosa
Responsible party
Amy Ellis (Assistant Professor, University of Alabama, Tuscaloosa) — Principal investigator
First posted
Aug 10, 2018
Start date
Feb 16, 2016
Primary completion
May 12, 2018
Completion
May 12, 2018
Results posted
May 17, 2022
Last update
May 17, 2022

Study contacts

Amy C Ellis, PhD, RD
principal investigator · University of Alabama at Birmingham
Kristi Crowe-White, PhD, RD
principal investigator · University of Alabama at Birmingham

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion